What does the evidence say about Taurine Blood Pressure Systematic Review?

The current Migaku evidence database contains 2 reusable source documents for Taurine Blood Pressure Systematic Review. This answer focuses on benefits, uncertainty, and practical interpretation. - BACKGROUND: SARS-CoV-2 infection can induce cellular senescence, resulting in chronic inflammation and senescence-associated secretory phenotype observed in post-acute sequalae of COVID-19 (PASC). [Wang K (2026); evidence level 1] - Preclinical evidence suggests taurine protects against cellular senescence, telomerase deficiency, DNA damage, and mitochondrial dysfunction, indicating its potential therapeutic role in PASC. [Wang K (2026); evidence level 1] - METHODS: We systemically searched MEDLINE, Embase, Cochrane Library, and Scopus through 21st March 2025 for clinical trials investigating taurine supplementation in systemic perturbations associated with PASC. [Wang K (2026); evidence level 1] - Taurine, a conditionally essential amino acid with potent anti-inflammatory and antioxidant properties, is naturally upregulated during COVID-19 convalescence. [Wang K (2026); evidence level 1] - Recent experimental evidence suggests that taurine (2-aminoethanesulfonic acid) deficiency contributes to these conditions, despite taurine being classified as a conditionally essential amino acid. [Chu MHM (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.